دورية أكاديمية
Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis.
| العنوان: | Metastatic Melanoma: A Preclinical Model Standardization and Development of a Chitosan-Coated Nanoemulsion Containing Temozolomide to Treat Brain Metastasis. |
|---|---|
| المؤلفون: | Gelsleichter NE; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil., de Souza PO; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil., Teixeira FC; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil., Debom GN; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil., Lenz GS; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil., Roliano GG; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil., de Cássia Sant'ana R; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil., Visioli F; Faculdade de Odontologia, Universidade Federal Do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil., Fachel FNS; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil., Michels LR; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil., Azambuja JH; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil., Teixeira HF; Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade Federal do Rio Grande Do Sul (UFRGS), Porto Alegre, RS, Brazil., Braganhol E; Programa de Pós-Graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Sarmento Leite Street, 245, Centro Histórico, Porto Alegre, RS, 90050-170, Brazil. ebraganhol@ufcspa.edu.br.; Instituto de Cardiologia do Rio Grande do Sul/Fundação Universitária do Instituto de Cardiologia (IC-FUC), Porto Alegre, RS, Brazil. ebraganhol@ufcspa.edu.br. |
| المصدر: | Cellular and molecular neurobiology [Cell Mol Neurobiol] 2023 Aug; Vol. 43 (6), pp. 2939-2951. Date of Electronic Publication: 2023 Apr 13. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 8200709 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-6830 (Electronic) Linking ISSN: 02724340 NLM ISO Abbreviation: Cell Mol Neurobiol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1999- : New York : Kluwer Academic/Plenum Publishers Original Publication: New York : Plenum Press, c1981- |
| مواضيع طبية MeSH: | Chitosan* , Melanoma*/drug therapy , Melanoma*/pathology , Melanoma*/secondary , Brain Neoplasms*/drug therapy , Brain Neoplasms*/secondary, Humans ; Animals ; Mice ; Temozolomide/pharmacology ; Temozolomide/therapeutic use ; Dacarbazine/pharmacology ; Dacarbazine/therapeutic use ; Cell Line, Tumor |
| مستخلص: | Melanoma is the most aggressive type of skin cancer. Brain metastasis is the worst scenario in metastatic melanoma and the treatment options for these patients are limited. Temozolomide (TMZ) is a chemotherapy agent used to treat primary central nervous system tumors. Our objective was to develop chitosan-coated nanoemulsion containing temozolomide (CNE-TMZ) for nasal route administration to melanoma brain metastasis treatment. A preclinical model of metastatic brain melanoma was standardized, and the efficiency of the developed formulation was further determined in vitro and in vivo. The nanoemulsion was done by spontaneous emulsification method and the formulation was characterized by size, pH, polydispersity index, and zeta potential. Culture assessments to determine cell viability were done in the A375 human melanoma cell line. To determine the safety of formulation, healthy C57/BL6 mice were treated with a nanoemulsion without TMZ. The model in vivo used B16-F10 cells implanted by stereotaxic surgery in C57/BL6 mice brains. The results demonstrate that the preclinical model used showed to be useful to analyze the efficiency of new candidate drugs to treat melanoma brain metastasis. The chitosan-coated nanoemulsions with TMZ showed the expected physicochemical characteristics and demonstrated safety and efficacy, reducing around 70% the tumor size compared to control mice, and presenting a tendency in mitotic index reduction, becoming an interesting approach to treat melanoma brain metastasis. (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| References: | Adnet T et al (2020) Pharmacotechnical development of a nasal drug delivery composite nanosystem intended for alzheimer’s disease treatment. Pharmaceutics. https://doi.org/10.3390/pharmaceutics12030251. (PMID: 10.3390/pharmaceutics12030251321687677151011) Azambuja JH et al (2020) Nasal administration of cationic nanoemulsions as CD73-siRNA delivery system for glioblastoma treatment: a new therapeutical approach. Mol Neurobiol. https://doi.org/10.1007/s12035-019-01730-6. (PMID: 10.1007/s12035-019-01730-631407144) Azimi F et al (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. https://doi.org/10.1200/JCO.2011.37.8539. (PMID: 10.1200/JCO.2011.37.853922711850) Baldrick P (2010) The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. https://doi.org/10.1016/j.yrtph.2009.09.015. (PMID: 10.1016/j.yrtph.2009.09.01520937341) Bobek V et al (2010) A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma. Antiancer Res 30(12):4799–4803. Bogunovic D et al (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.0905139106. (PMID: 10.1073/pnas.0905139106199151472787158) Bruinsmann FA et al (2019) Nasal drug delivery of anticancer drugs for the treatment of glioblastoma: preclinical and clinical trials. Molecules. https://doi.org/10.3390/molecules24234312. (PMID: 10.3390/molecules24234312317791266930669) Calderó G, García-Celma M, Solans C (2010) Formation of polymeric nano-emulsions by a low-energy method and their use for nanoparticle preparation. J Colloid Interface Sci 353:406–411. https://doi.org/10.1016/j.jcis.2010.09.073. (PMID: 10.1016/j.jcis.2010.09.07320971472) Chiarion-Sileni V et al (2011) Central nervous system failure in melanoma patients: Results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine-based regimens. Br J Cancer. https://doi.org/10.1038/bjc.2011.178. (PMID: 10.1038/bjc.2011.178216107113111207) Clemente N et al (2018) ‘Solid lipid nanoparticles carrying temozolomide for melanoma treatment. Preliminary in vitro and in vivo studies. Int J Mol Sci. https://doi.org/10.3390/ijms19020255. (PMID: 10.3390/ijms19020255293641575855544) Davies MA et al (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer. https://doi.org/10.1002/cncr.25634. (PMID: 10.1002/cncr.2563422180178) De Matteis L et al (2016) Controlling properties and cytotoxicity of chitosan nanocapsules by chemical grafting. Mar Drugs. https://doi.org/10.3390/md14100175. (PMID: 10.3390/md14100175277060415082323) Dianzani C, Monge C, Miglio G, Serpe L, Martina K, Cangemi L, Ferraris C, Mioletti S, Osella S, Gigliotti CL, Boggio E, Clemente N, Dianzani U, Battaglia L (2020) Nanoemulsions as delivery systems for poly-chemotherapy aiming at melanoma treatment. Cancers (Basel) 12(5):1198. https://doi.org/10.3390/cancers12051198. (PMID: 10.3390/cancers1205119832397484) Erdei E, Torres SM (2010) A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther 10(11):1811–1823. https://doi.org/10.1586/era.10.170. (PMID: 10.1586/era.10.170210808063074354) Fachel FNS et al (2018) Box-Behnken design optimization of mucoadhesive chitosan-coated nanoemulsions for rosmarinic acid nasal delivery—in vitro studies. Carbohyd Polym. https://doi.org/10.1016/j.carbpol.2018.07.054. (PMID: 10.1016/j.carbpol.2018.07.054) Fachel FNS, Michels LR, Azambuja JH, Lenz GS, Gelsleichter NE, Endres M, Scholl JN, Schuh RS, Barschak AG, Figueiró F, Bassani VL, Henriques AT, Koester LS, Teixeira HF, Braganhol E (2020) Chitosan-coated rosmarinic acid nanoemulsion nasal administration protects against LPS-induced memory deficit, neuroinflammation, and oxidative stress in Wistar rats. Neurochem Int. https://doi.org/10.1016/j.neuint.2020.104875. (PMID: 10.1016/j.neuint.2020.10487533039443) Fan Y et al (2018) Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases. Crit Rev Ther Drug Carrier Syst 35(5):433–467. https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2018024697. (PMID: 10.1615/CritRevTherDrugCarrierSyst.201802469730317945) Ferraro MG et al (2020) Breast cancer chemotherapeutic options: a general overview on the preclinical validation of a multi-target Ruthenium(III) complex lodged in nucleolipid nanosystems. Cells. https://doi.org/10.3390/cells9061412. (PMID: 10.3390/cells9061412325171017349411) Ho BN, Pfeffer CM, Singh ATK (2017) Update on Nanotechnology-based Drug Delivery Systems in Cancer Treatment 5981:5975–5981. https://doi.org/10.21873/anticanres.12044. In GK, Poorman K, Saul M, O’Day S, Farma JM, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, Weise A, Daveluy S, Gibney G, Atkins MB, Vanderwalde A (2020) Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget 11(33):3118–3128. https://doi.org/10.18632/oncotarget.27686.=. (PMID: 10.18632/oncotarget.27686.=329135567443369) Intakhab Alam M et al (2011) Nanostructured lipid carrier containing CNS acting drug: formulation, optimization and evaluation. Curr Nanosci 7(6):1014–1027. https://doi.org/10.2174/1573413711107061014. (PMID: 10.2174/1573413711107061014) Ishak RAH et al (2013) A comparative study of chitosan shielding effect on nano-carriers hydrophilicity and biodistribution. Carbohyd Polym 94(1):669–676. https://doi.org/10.1016/j.carbpol.2013.01.072. (PMID: 10.1016/j.carbpol.2013.01.072) Jiang G et al (2017) Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells. Oncol Rep 37(2):995–1001. https://doi.org/10.3892/or.2016.5342. (PMID: 10.3892/or.2016.534228035395) Khan A et al (2016) Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses. Mol Pharm 13(11):3773–3782. https://doi.org/10.1021/acs.molpharmaceut.6b00586. (PMID: 10.1021/acs.molpharmaceut.6b0058627661966) Kim SS et al (2015) Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma. Cancer Lett. https://doi.org/10.1016/j.canlet.2015.08.022. (PMID: 10.1016/j.canlet.2015.08.022267238784919239) Kim YS, Shin S, Yin JH, Park J, Jung SH, Chung YJ (2022) Single-cell RNA sequencing reveals the existence of pro-metastatic subpopulation within a parental B16 murine melanoma cell line. Biochem Biophys Res Commun 12(613):120–126. https://doi.org/10.1016/j.bbrc.2022.05.003. (PMID: 10.1016/j.bbrc.2022.05.003) Kircher DA et al (2016) Melanoma brain metastasis: mechanisms, models, and medicine. Int J Mol Sci. https://doi.org/10.3390/ijms17091468. (PMID: 10.3390/ijms17091468275981485037746) Kong L et al (2011) Melanoma in a murine model 16(9):2550–2561. https://doi.org/10.1158/1078-0432.CCR-10-0279.Inhibition. Korn EL et al (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. https://doi.org/10.1200/JCO.2007.12.7837. (PMID: 10.1200/JCO.2007.12.7837190649772645857) Lebre F et al (2016) Intranasal Administration of Novel Chitosan nanoparticle/DNA complexes induces antibody response to Hepatitis B surface antigen in Mice. Mol Pharm. https://doi.org/10.1021/acs.molpharmaceut.5b00707. (PMID: 10.1021/acs.molpharmaceut.5b0070726651533) Lee JYK et al (2000) Brain surgery with image guidance: current recommendations based on a 20-year assessment. Stereotact Funct Neurosurg. https://doi.org/10.1159/000048381. (PMID: 10.1159/00004838111416263) Li R-H et al (2015) Temozolomide for treating malignant melanoma. J Coll Phys Surg Pak 25(9): 680–688. 09.2015/JCPSP.680688. Linos E et al (2009) Increasing burden of melanoma in the United States. J Investig Dermatol 129(7):1666–1674. https://doi.org/10.1038/jid.2008.423. (PMID: 10.1038/jid.2008.42319131946) Matica A, Menghiu G, Ostafe V (2017) Biodegradability of chitosan based products. New Front Chem 26:75–86. McDonald MA et al (2018) Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review. BMC Cancer. https://doi.org/10.1186/s12885-018-4470-y. (PMID: 10.1186/s12885-018-4470-y297430505943996) Michels LR, Fachel FNS, Azambuja JH, Gelsleichter NE, Braganhol E, Teixeira HF (2019) HPLC–UV method for temozolomide determination in complex biological matrices: application for in vitro, ex vivo and in vivo studies. Biomed Chromatogr. https://doi.org/10.1002/bmc.4615. (PMID: 10.1002/bmc.461531166608) Michels LR, Fachel FNS, Schuh RS, Azambuja JH, de Souza PO, Gelsleichter NE, Lenz GS, Visioli F, Braganhol E, Teixeira HF (2023) Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model. J Control Release 355:343–357. https://doi.org/10.1016/j.jconrel.2023.01.070. (PMID: 10.1016/j.jconrel.2023.01.07036731799) Miyake MM, Bleier BS (2015) The blood-brain barrier and nasal drug delivery to the central nervous system. Am J Rhinol Allergy 29(2):124–127. https://doi.org/10.2500/ajra.2015.29.4149. (PMID: 10.2500/ajra.2015.29.414925785753) Pantshwa JM et al (2020) Nanodrug delivery systems for the treatment of ovarian cancer. Cancers. https://doi.org/10.3390/cancers12010213. (PMID: 10.3390/cancers12010213319522107017423) Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold TW (2009) The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15(22):7092–7098. https://doi.org/10.1158/1078-0432.CCR-09-1349. (PMID: 10.1158/1078-0432.CCR-09-1349198614332908372) Prego C et al (2005) Transmucosal macromolecular drug delivery. J Controll Release. https://doi.org/10.1016/j.jconrel.2004.07.030. Propet B (1994) Laboratory methods in histotechnology. laboratory manuals: manual of histologic staining methods of the Armed Forces Institute of Pathology. American Registry of Pathology, Washington, D.C. [viii, 279 p. : ill. (some col.) ; 26 cm]. Riss TL et al (2004) Cell viability assays, assay guidance manual. In: Assay guidance manual. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences. https://www.ncbi.nlm.nih.gov/pubmed/23805433. Sabit H, Kaliyadan F, Menezes R (2020) Malignant melanoma: underlying epigenetic mechanisms. Indian J Dermatol Venereol Leprol. https://doi.org/10.4103/ijdvl.ijdvl_791_19. (PMID: 10.4103/ijdvl.ijdvl_791_1932769310) Soni V, Adhikari M, Simonyan H, Lin L, Sherman JH, Young CN, Keidar M (2021) In vitro and in vivo enhancement of Temozolomide effect in human glioblastoma by non-invasive application of cold atmospheric plasma. Cancers 13:4485. https://doi.org/10.3390/cancers13174485. (PMID: 10.3390/cancers13174485345032938430547) Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol. https://doi.org/10.1186/1745-6673-2-16. (PMID: 10.1186/1745-6673-2-16180531522222591) Tas F (2012) Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. https://doi.org/10.1155/2012/647684. (PMID: 10.1155/2012/647684227921023391929) Tapola NS et al (2008) Safety aspects and cholesterol-lowering efficacy of chitosan tablets. J Am Coll Nutr. https://doi.org/10.1080/07315724.2008.10719671. (PMID: 10.1080/07315724.2008.1071967118460478) Teimouri F, Nikfar S, Abdollahi M (2013) Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. Melanoma Res. https://doi.org/10.1097/CMR.0b013e3283649a97. (PMID: 10.1097/CMR.0b013e3283649a9723880781) Timmons JJ, Cohessy S, Wong ET (2016) (2016) ‘Injection of syngeneic murine melanoma cells to determine their metastatic potential in the lungs.’ J vis Exp 111:4–7. https://doi.org/10.3791/54039. (PMID: 10.3791/54039) Trinh VA, Patel SP, Hwu WJ (2009) The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8(4):493–499. https://doi.org/10.1517/14740330902918281. (PMID: 10.1517/1474033090291828119435405) World Health Organization (2020) ‘No Title’. https://www.who.int/uv/resources/FAQ/skincancer/en/index2.html. Young GJ et al (2017) Management of intracranial melanomas in the era of precision medicine. Oncotarget. https://doi.org/10.18632/oncotarget.19223. (PMID: 10.18632/oncotarget.19223294640615814201) Zhu W et al (2014) Temozolomide for treatment of brain metastases: A review of 21 clinical trials. World J Clin Oncol. https://doi.org/10.5306/wjco.v5.i1.19. (PMID: 10.5306/wjco.v5.i1.19248298654014790) |
| معلومات مُعتمدة: | 001 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; 422298/2016-6 Conselho Nacional de Desenvolvimento Científico e Tecnológico; 310846/2014-5 Conselho Nacional de Desenvolvimento Científico e Tecnológico; 16/2551-0000265-7 Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul; 16/2551-0000473-0 Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul |
| فهرسة مساهمة: | Keywords: Brain metastasis; Chitosan; Melanoma; Nanoemulsion; Temozolomide |
| المشرفين على المادة: | YF1K15M17Y (Temozolomide) 9012-76-4 (Chitosan) 7GR28W0FJI (Dacarbazine) |
| تواريخ الأحداث: | Date Created: 20230413 Date Completed: 20230712 Latest Revision: 20230718 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1007/s10571-023-01338-4 |
| PMID: | 37055607 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1573-6830 |
|---|---|
| DOI: | 10.1007/s10571-023-01338-4 |